|
|
News Breaks | | | | December 31, 2012 | | 13:27 EDT |  | SLXP | FDA approves anti-diarrheal drug for HIV/AIDS patients distributed by Salix
The U.S. Food and Drug Administration approved Fulyzaq to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection. Before treating patients with Fulyzaq, health care professionals should conduct proper testing to confirm the diarrhea is not caused by an infection or a gastrointestinal disease. Common side effects reported in patients taking Fulyzaq in the clinical trial were upper respiratory tract infection, bronchitis, cough, flatulence, and increased levels of the liver enzyme bilirubin. Fulyzaq is distributed by Salix Pharmaceuticals under license from Napo Pharmaceuticals. | |
|
News For SLXP From The Last 14 Days Check below for free stories on SLXP the last two weeks. |
|
|
| May 23, 2013 | | 12:35 EDT |  | SLXP | Salix management to meet with Jefferies
 Subscribe for More Information | | | May 22, 2013 | | 07:07 EDT | | SLXP | Salix announces statistically significant results for budesonide foam
Salix Pharmaceuticals announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis, UP, or ulcerative proctosigmoiditis, UPS. In each of the two pivotal Phase 3 studies, a statistically significant proportion of subjects treated with budesonide foam achieved clinical remission compared to subjects treated with placebo foam. The company said, “We are pleased with the outcome of our pivotal studies of budesonide foam in the treatment of UP and UPS...We believe foam formulations provide important advantages over enema formulations principally with respect to drug retention and patient acceptance. We are working to submit a New Drug Application for budesonide foam as a treatment for UP and UPS by the end of September 2013. If approved, budesonide foam would be the first foam product approved in the United States for patients with UP...as well as for patients suffering from UPS." | | | May 17, 2013 | | 10:36 EDT | | SLXP | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information | |
|
|
|
|
|
|
